JP2023543218A5 - - Google Patents
Info
- Publication number
- JP2023543218A5 JP2023543218A5 JP2023518775A JP2023518775A JP2023543218A5 JP 2023543218 A5 JP2023543218 A5 JP 2023543218A5 JP 2023518775 A JP2023518775 A JP 2023518775A JP 2023518775 A JP2023518775 A JP 2023518775A JP 2023543218 A5 JP2023543218 A5 JP 2023543218A5
- Authority
- JP
- Japan
- Prior art keywords
- expression
- repressor
- dna sequence
- binding
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063082555P | 2020-09-24 | 2020-09-24 | |
| US63/082,555 | 2020-09-24 | ||
| US202163242957P | 2021-09-10 | 2021-09-10 | |
| US63/242,957 | 2021-09-10 | ||
| PCT/US2021/051945 WO2022067033A1 (en) | 2020-09-24 | 2021-09-24 | Compositions and methods for inhibiting gene expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023543218A JP2023543218A (ja) | 2023-10-13 |
| JP2023543218A5 true JP2023543218A5 (cg-RX-API-DMAC7.html) | 2024-10-02 |
Family
ID=80845810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023518775A Pending JP2023543218A (ja) | 2020-09-24 | 2021-09-24 | 遺伝子発現を阻害するための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230399640A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4217477A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023543218A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230074525A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021350024A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023003424A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022067033A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| WO2018049075A1 (en) | 2016-09-07 | 2018-03-15 | Flagship Pioneering, Inc. | Methods and compositions for modulating gene expression |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| EP4240367A4 (en) | 2020-11-04 | 2024-10-16 | Myeloid Therapeutics, Inc. | MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF |
| KR20240013094A (ko) | 2021-03-17 | 2024-01-30 | 마이얼로이드 테라퓨틱스, 인크. | 조작된 키메라 융합 단백질 조성물 및 그의 사용 방법 |
| WO2022241029A1 (en) | 2021-05-11 | 2022-11-17 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| US20250236854A1 (en) * | 2021-10-05 | 2025-07-24 | Glaxosmithkline Intellectual Property Development Limited GSK Medicines Research Centre | Crispr/cas9-based fusion proteins for modulating gene expression and methods of use |
| WO2024040254A2 (en) * | 2022-08-19 | 2024-02-22 | Tune Therapeutics, Inc. | Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression |
| KR20250128349A (ko) * | 2022-12-23 | 2025-08-27 | 에피제닉 테라퓨틱스 피티이 리미티드 | 융합체 및 이의 용도 |
| JP2026518711A (ja) | 2023-05-16 | 2026-06-09 | フラッグシップ ラブズ 114, インコーポレイテッド | 標的遺伝子のメチル化を調節するための方法及び組成物 |
| WO2024238723A1 (en) | 2023-05-16 | 2024-11-21 | Omega Therapeutics, Inc. | Methods and compositions for modulating pcsk9 expression |
| WO2025019742A1 (en) | 2023-07-19 | 2025-01-23 | Omega Therapeutics, Inc. | Methods and compositions for modulating ctnnb1 expression |
| WO2025064469A1 (en) * | 2023-09-18 | 2025-03-27 | Omega Therapeutics, Inc. | Methods for assessing dosage for epigenetic modifying agents |
| WO2025171047A1 (en) * | 2024-02-05 | 2025-08-14 | Bioventures, Llc | Leveraging cancer-evolved resistance mechanisms to enhance ezh2 activity in adoptive t cells |
| WO2025261475A1 (zh) * | 2024-06-21 | 2025-12-26 | 益杰立科(上海)生物科技有限公司 | 靶向血管内皮生长因子的工程化基因转录阻抑工具及用途 |
| WO2026064556A1 (en) * | 2024-09-19 | 2026-03-26 | Arc Research Institute | Epigenetic modulation system |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2728782T3 (es) * | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| GB201418965D0 (cg-RX-API-DMAC7.html) * | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
| AU2016308339A1 (en) * | 2015-08-18 | 2018-04-12 | Baylor College Of Medicine | Methods and compositions for altering function and structure of chromatin loops and/or domains |
| US9896696B2 (en) * | 2016-02-15 | 2018-02-20 | Benson Hill Biosystems, Inc. | Compositions and methods for modifying genomes |
| EP3867368A4 (en) * | 2018-10-15 | 2022-08-10 | Flagship Pioneering Innovations V, Inc. | DESTROYING THE ASSEMBLY OF A GENOMIC COMPLEX IN FUSION GENES |
| WO2020160125A1 (en) * | 2019-01-29 | 2020-08-06 | Flagship Pioneering Innovations V, Inc. | Compositions comprising an endonuclease and methods for purifying an endonuclease |
-
2021
- 2021-09-24 WO PCT/US2021/051945 patent/WO2022067033A1/en not_active Ceased
- 2021-09-24 MX MX2023003424A patent/MX2023003424A/es unknown
- 2021-09-24 AU AU2021350024A patent/AU2021350024A1/en active Pending
- 2021-09-24 EP EP21873514.0A patent/EP4217477A4/en active Pending
- 2021-09-24 KR KR1020237013601A patent/KR20230074525A/ko not_active Withdrawn
- 2021-09-24 US US18/246,480 patent/US20230399640A1/en active Pending
- 2021-09-24 JP JP2023518775A patent/JP2023543218A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12246061B2 (en) | Sequence specific antimicrobials | |
| Langley et al. | Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents | |
| Dai et al. | Classical HDACs in the regulation of neuroinflammation | |
| Glajch et al. | Epigenetic mechanisms involved in Huntington's disease pathogenesis | |
| JP2022527108A5 (cg-RX-API-DMAC7.html) | ||
| Sinha et al. | PARP1-modulated chromatin remodeling is a new target for cancer treatment | |
| Rojewska et al. | PD98059 influences immune factors and enhances opioid analgesia in model of neuropathy | |
| HUP9902103A2 (hu) | Triarilvegyületek | |
| EP3632901A1 (en) | Histone acetyltransferase activators and uses thereof | |
| CN103763921B (zh) | 组蛋白乙酰转移酶激活剂的用途 | |
| PH12022552237A1 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| Hurst | Metastasis suppression by BRMS1 associated with SIN3 chromatin remodeling complexes | |
| PH12022552238A1 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| JP2022512974A5 (cg-RX-API-DMAC7.html) | ||
| JP2023543056A5 (cg-RX-API-DMAC7.html) | ||
| MX2022012844A (es) | Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos. | |
| CA3193868A1 (en) | Compositions and methods for inhibiting the expression of multiple genes | |
| JP5788907B2 (ja) | 疾患の治療に使用される化合物 | |
| CN118681022A (zh) | 治疗高毒力肺炎克雷伯菌感染的方法 | |
| Urnov et al. | Chromatin organisation and human disease | |
| JP7153947B2 (ja) | 口腔の炎症の治療のために用いられるイヌicam-1に対するアンチセンス薬物 | |
| JP2002512029A5 (cg-RX-API-DMAC7.html) | ||
| WO2023288240A8 (en) | Antisense oligonucleotide (aso) gene inhibition and treatment | |
| EP4595976A1 (en) | Composition for treating cancer containing histone deacetylase inhibitor, and anticancer adjuvant for cancer immunotherapy | |
| US20040265286A1 (en) | Method of lethally sensitizing human and animal cells |